Xagenic Looks To Launch Point-of-Care Molecular Dx Platform Targeting Infectious Disease
This article was originally published in The Pink Sheet Daily
The start-up has created the Xagenic X1 platform to run molecular diagnostic tests in a physician's office in about 20 minutes instead of sending samples out to a lab.
You may also be interested in...
The company’s leadership discussed its recent investments in robotic surgery technology during Johnson & Johnson’s 2019 fourth-quarter earnings call on 22 January. The company will provide more information on its robotic surgery platforms at its investors meeting in May in New York.
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.
The US FDA approved fewer novel devices in 2019 than in 2018, despite a slight increase in original PMA approvals. De novo clearances were down significantly after four straight years of increases, while panel-track PMA supplements and 510(k) clearances also declined from the 2018 totals.